CHRO

Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’

PremiumThe Fly

3d ago

PremiumThe Fly

FDA shift in drug study requirements sends trial runners lower

4d ago

FDA to reduce number of trials required for drug approvals, STAT reports

PremiumThe Fly

4d ago

FDA to reduce number of trials required for drug approvals, STAT reports

PremiumThe Fly

4d ago

PremiumThe FlyRoche price target raised to CHF 290 from CHF 255 at Morgan Stanley

6d ago

Roche price target raised to CHF 300 from CHF 290 at Berenberg

The Fly

Roche price target raised to CHF 300 from CHF 290 at Berenberg

6d ago

Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports

The Fly

Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports

6d ago

Vaccine committee considers changes to childhood schedule, NY Times reports

PremiumThe Fly

6d ago

Roche receives FDA clearance with CLIA waiver for pertussis point-of-care test

PremiumThe Fly

6d ago

Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK

PremiumThe Fly

7d ago

PremiumThe Fly

Trump Trade: U.S. confirms agreement with U.K. on pharmaceutical pricing

7d ago

PremiumThe FlyUS government confirms agreement in principle with UK on pharmaceutical pricing

7d ago

US, UK expected to agree on zero-tariffs pharmaecuticals deal, UK Times says

The Fly

US, UK expected to agree on zero-tariffs pharmaecuticals deal, UK Times says

7d ago

Oppenheimer says Roche’s commitment to Veeva Vault CRM carries greater weight

The Fly

Oppenheimer says Roche’s commitment to Veeva Vault CRM carries greater weight

14d ago

Lineage Cell says first OpRegen development milestone under Roche pact achieved

VEEV

PremiumThe Fly

14d ago

Lineage Cell’s OpRegen shows evidence of progress, says H.C. Wainwright

LCTX

PremiumThe Fly

14d ago

Prothena price target raised to $8 from $4 at BofA

LCTX

PremiumThe Fly

14d ago

NVO

Veeva announces expanded partnership with Roche Pharmaceuticals

PremiumThe Fly

14d ago

VEEV

PremiumThe FlyOlema Oncology price target raised to $40 from $20 at Guggenheim

18d ago

OLMA

Roche announces EC granted conditional marketing approval of Lunsumio SC

The Fly

Roche announces EC granted conditional marketing approval of Lunsumio SC

19d ago

Olema Oncology price target raised to $45 from $22 at Oppenheimer

The Fly

Olema Oncology price target raised to $45 from $22 at Oppenheimer

20d ago